Ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome
The National Health Care Institute has completed its assessment whether ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome, can be accepted into the Medicine Reimbursement System (GVS).
Registered indication
Ciclosporin 0.1% (Ikervis®) is registered for the treatment of severe keratitis in adult patients with dry eye syndrome which has not improved despite treatment with tear substitutes. Ikervis® is available as a cationic emulsion containing 0.1% ciclosporin. Each ml contains 1 mg ciclosporin. The recommended dose is one drop of Ikervis® once daily to be applied to the affected eye(s) at bedtime.
The National Health Care Institute's advice
The National Health Care Institute advices the Minister of Health, Welfare and Sport (VWS) to accept ciclosporin (Ikervis®) into the Medicine Reimbursement System (GVS). Based on the criteria for interchangeability, ciclosporin 0.1% (Ikervis®) is not eligible for inclusion on List 1A. Based on the mentioned considerations in the assessment, the National Health Care Institute advises the Minister to include ciclosporin 0.1% (Ikervis®) on List 1B of the Health Insurance Decree. There is no reimbursement limit for medicinal products on this list.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.